Physician profile
Forrest Ray Powers
NPI 1235556366
$12,012.42
in general payments reported to CMS, 2019-2025
24 companies · $7,339 in 2025
The $7,339 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $1,136 · 2021: $1,197 · 2022: $1,123 · 2023: $686 · 2025: $7,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Food and Beverage: $732 · Travel and Lodging: $694 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Food and Beverage | $732.19 |
| Travel and Lodging | $693.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $7,338.60 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $1,014.34 | 2019-2023 | |
| Janssen Biotech, INC. | $806.21 | 2020-2023 | Tremfya, Stelara, Simponi |
| Amgen INC. | $615.47 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $401.06 | 2020-2023 | Cimzia |
| Lilly USA, LLC | $271.73 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $268.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $255.01 | 2020-2021 | |
| Pfizer INC. | $189.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $158.32 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $143.96 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $121.03 | 2020-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.80 | 2019-2021 | |
| Nevro Corp. | $68.20 | 2022 | |
| Glaxosmithkline, LLC. | $60.53 | 2022-2023 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $41.36 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $35.54 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $28.57 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.12 | 2022 | |
| Celgene Corporation | $18.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $17.42 | 2019 | |
| Pacira Therapeutics, INC. | $15.73 | 2019 | |
| Genentech USA, INC. | $13.26 | 2019 | |
| Medexus Pharma, INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.